242 related articles for article (PubMed ID: 8654370)
1. Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.
Toniatti C; Cabibbo A; Sporena E; Salvati AL; Cerretani M; Serafini S; Lahm A; Cortese R; Ciliberto G
EMBO J; 1996 Jun; 15(11):2726-37. PubMed ID: 8654370
[TBL] [Abstract][Full Text] [Related]
2. Reversal of some viral IL-6 electrostatic properties compared to IL-6 contributes to a loss of alpha receptor component recruitment.
Perret D; Rousseau F; Tran V; Gascan H
Proteins; 2005 Jul; 60(1):14-26. PubMed ID: 15861391
[TBL] [Abstract][Full Text] [Related]
3. Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding.
Hammacher A; Ward LD; Weinstock J; Treutlein H; Yasukawa K; Simpson RJ
Protein Sci; 1994 Dec; 3(12):2280-93. PubMed ID: 7538847
[TBL] [Abstract][Full Text] [Related]
4. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.
Boulanger MJ; Chow DC; Brevnova EE; Garcia KC
Science; 2003 Jun; 300(5628):2101-4. PubMed ID: 12829785
[TBL] [Abstract][Full Text] [Related]
5. Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.
Kurth I; Horsten U; Pflanz S; Dahmen H; Küster A; Grötzinger J; Heinrich PC; Müller-Newen G
J Immunol; 1999 Feb; 162(3):1480-7. PubMed ID: 9973404
[TBL] [Abstract][Full Text] [Related]
6. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor.
Skiniotis G; Boulanger MJ; Garcia KC; Walz T
Nat Struct Mol Biol; 2005 Jun; 12(6):545-51. PubMed ID: 15895091
[TBL] [Abstract][Full Text] [Related]
7. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction.
Ehlers M; Grötzinger J; deHon FD; Müllberg J; Brakenhoff JP; Liu J; Wollmer A; Rose-John S
J Immunol; 1994 Aug; 153(4):1744-53. PubMed ID: 7519211
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
[TBL] [Abstract][Full Text] [Related]
9. Structure of an extracellular gp130 cytokine receptor signaling complex.
Chow D; He X; Snow AL; Rose-John S; Garcia KC
Science; 2001 Mar; 291(5511):2150-5. PubMed ID: 11251120
[TBL] [Abstract][Full Text] [Related]
10. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
11. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.
Thabard W; Barillé S; Collette M; Harousseau JL; Rapp MJ; Bataille R; Amiot M
Clin Cancer Res; 1999 Oct; 5(10):2693-7. PubMed ID: 10537331
[TBL] [Abstract][Full Text] [Related]
12. Monovalent phage display of human interleukin (hIL)-6: selection of superbinder variants from a complex molecular repertoire in the hIL-6 D-helix.
Cabibbo A; Sporeno E; Toniatti C; Altamura S; Savino R; Paonessa G; Ciliberto G
Gene; 1995 Dec; 167(1-2):41-7. PubMed ID: 8566809
[TBL] [Abstract][Full Text] [Related]
13. Notch ligand Delta-1 differentially modulates the effects of gp130 activation on interleukin-6 receptor alpha-positive and -negative human hematopoietic progenitors.
Yamamura K; Ohishi K; Katayama N; Kato K; Shibasaki T; Sugimoto Y; Miyata E; Shiku H; Masuya M; Nishioka J; Nobori T; Nishikawa M; Inagaki Y; Hiramatsu H; Nakahata T
Cancer Sci; 2007 Oct; 98(10):1597-603. PubMed ID: 17645774
[TBL] [Abstract][Full Text] [Related]
14. In vitro reconstitution of recognition and activation complexes between interleukin-6 and gp130.
Chow D; Ho J; Nguyen Pham TL; Rose-John S; Garcia KC
Biochemistry; 2001 Jun; 40(25):7593-603. PubMed ID: 11412113
[TBL] [Abstract][Full Text] [Related]
15. Solution structure of recombinant human interleukin-6.
Xu GY; Yu HA; Hong J; Stahl M; McDonagh T; Kay LE; Cumming DA
J Mol Biol; 1997 May; 268(2):468-81. PubMed ID: 9159484
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6.
Boulanger MJ; Chow DC; Brevnova E; Martick M; Sandford G; Nicholas J; Garcia KC
J Mol Biol; 2004 Jan; 335(2):641-54. PubMed ID: 14672670
[TBL] [Abstract][Full Text] [Related]
17. IL-6 signal transduction and its physiological roles: the signal orchestration model.
Kamimura D; Ishihara K; Hirano T
Rev Physiol Biochem Pharmacol; 2003; 149():1-38. PubMed ID: 12687404
[TBL] [Abstract][Full Text] [Related]
18. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes.
Grötzinger J; Kurapkat G; Wollmer A; Kalai M; Rose-John S
Proteins; 1997 Jan; 27(1):96-109. PubMed ID: 9037715
[TBL] [Abstract][Full Text] [Related]
19. Structural requirements for gp80 independence of human herpesvirus 8 interleukin-6 (vIL-6) and evidence for gp80 stabilization of gp130 signaling complexes induced by vIL-6.
Chen D; Nicholas J
J Virol; 2006 Oct; 80(19):9811-21. PubMed ID: 16973585
[TBL] [Abstract][Full Text] [Related]
20. Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization.
Suthaus J; Adam N; Grötzinger J; Scheller J; Rose-John S
Eur J Cell Biol; 2011; 90(6-7):495-504. PubMed ID: 21176991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
